Literature DB >> 33440670

Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review.

Johanna Raymond1,2, Laurent Imbert2,3, Thibault Cousin1, Thomas Duflot3, Rémi Varin1, Julien Wils2,3, Fabien Lamoureux2,3.   

Abstract

Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pharmacogenetics (RNPGx), the management of some treatments in cardiovascular diseases (as antiplatelet agents, oral vitamin K antagonists, and statins) can rely on genetic testing in order to improve healthcare by reducing therapeutic resistance or toxicity. This paper is a review of association studies between single nucleotide polymorphisms (SNPs) and systemic exposure variation of DOACs. Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Regarding edoxaban and betrixaban, as well as SNPs in the CYP3A4 and CYP3A5 genes, literature is scarce, and further studies are needed.

Entities:  

Keywords:  adverse drug reactions; clinical implementation; direct oral anticoagulants; pharmacogenetics

Year:  2021        PMID： 33440670      PMCID： PMC7826504          DOI： 10.3390/jpm11010037

Source DB:  PubMed          Journal:  J Pers Med        ISSN： 2075-4426


  48 in total

1.  dbSNP: the NCBI database of genetic variation.

Authors:  S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

Review 2.  Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.

Authors:  Laurent Bertoletti; Edouard Ollier; Cécile Duvillard; Xavier Delavenne; Marie-Noëlle Beyens; Elodie De Magalhaes; Florelle Bellet; Thierry Basset; Patrick Mismetti; Silvy Laporte
Journal:  Pharmacol Res       Date:  2016-06-24       Impact factor: 7.658

Review 3.  Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

Authors:  Mike Ufer
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

4.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.

Authors:  Daniel M F Claassens; Gerrit J A Vos; Thomas O Bergmeijer; Renicus S Hermanides; Arnoud W J van 't Hof; Pim van der Harst; Emanuele Barbato; Carmine Morisco; Richard M Tjon Joe Gin; Folkert W Asselbergs; Arend Mosterd; Jean-Paul R Herrman; Willem J M Dewilde; Paul W A Janssen; Johannes C Kelder; Maarten J Postma; Anthonius de Boer; Cornelis Boersma; Vera H M Deneer; Jurriën M Ten Berg
Journal:  N Engl J Med       Date:  2019-09-03       Impact factor: 91.245

5.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

6.  The effect of food on the absorption and pharmacokinetics of rivaroxaban.

Authors:  Jan Stampfuss; Dagmar Kubitza; Michael Becka; Wolfgang Mueck
Journal:  Int J Clin Pharmacol Ther       Date:  2013-07       Impact factor: 1.366

7.  Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

Authors:  Kuntheavy Ing Lorenzini; Youssef Daali; Pierre Fontana; Jules Desmeules; Caroline Samer
Journal:  Front Pharmacol       Date:  2016-12-19       Impact factor: 5.810

8.  Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways.

Authors:  Andrea Huppertz; Caspar Grond-Ginsbach; Chris Dumschat; Kathrin I Foerster; Jürgen Burhenne; Johanna Weiss; David Czock; Jan C Purrucker; Timolaos Rizos; Walter E Haefeli
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-29       Impact factor: 2.483

9.  Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke.

Authors:  Alexander Valerevich Kryukov; Dmitry Alekseevich Sychev; Denis Anatolevich Andreev; Kristina Anatolievna Ryzhikova; Elena Anatolievna Grishina; Anastasia Vladislavovna Ryabova; Mark Alekseevich Loskutnikov; Valeriy Valerevich Smirnov; Olga Dmitrievna Konova; Irina Andreevna Matsneva; Pavel Olegovich Bochkov
Journal:  Pharmgenomics Pers Med       Date:  2018-03-22

10.  The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty.

Authors:  Dmitriy Alekseevich Sychev; Alexander Nikolaevich Levanov; Tatiana Vladimirovna Shelekhova; Pavel Olegovich Bochkov; Natalia Pavlovna Denisenko; Kristina Anatolyevna Ryzhikova; Karin Badavievich Mirzaev; Elena Anatolyevna Grishina; Mikhail Alekseevich Gavrilov; Galina Vladislavovna Ramenskaya; Aleksei Vladimirovich Kozlov; Tanya Bogoslovsky
Journal:  Pharmgenomics Pers Med       Date:  2018-07-25
View more
  15 in total

1.  The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation.

Authors:  Dmitry Sychev; Olga Ostroumova; Marina Cherniaeva; Nataliia Shakhgildian; Karin Mirzaev; Sherzod Abdullaev; Natalia Denisenko; Zhannet Sozaeva; Anastasia Kachanova; Svetlana Gorbatenkova; Vera Shastina
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-08-12

2.  Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Authors:  Mariana Babayeva; Brigitte Azzi; Zvi G Loewy
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice.

Authors:  Nicola Ferri; Elisa Colombo; Marco Tenconi; Ludovico Baldessin; Alberto Corsini
Journal:  Pharmaceutics       Date:  2022-05-24       Impact factor: 6.525

4.  Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.

Authors:  Camille Lenoir; Jean Terrier; Yvonne Gloor; Pauline Gosselin; Youssef Daali; Christophe Combescure; Jules Alexandre Desmeules; Caroline Flora Samer; Jean-Luc Reny; Victoria Rollason
Journal:  J Pers Med       Date:  2022-03-24

5.  Pharmacogenetics to Avoid Adverse Drug Reactions.

Authors:  Luis A López-Fernández
Journal:  J Pers Med       Date:  2022-01-26

6.  ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding - A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.

Authors:  Consolato M Sergi
Journal:  Case Rep Gastroenterol       Date:  2022-02-14

7.  Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment.

Authors:  Xi Zhang; Xiaolin Zhang; Fangnian Tong; Yi Cai; Yujie Zhang; Haixu Song; Xiaoxiang Tian; Chenghui Yan; Yaling Han
Journal:  Elife       Date:  2022-03-08       Impact factor: 8.140

Review 8.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

9.  Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting.

Authors:  Patrick Silva; David Jacobs; John Kriak; Asim Abu-Baker; George Udeani; Gabriel Neal; Kenneth Ramos
Journal:  J Pers Med       Date:  2021-05-21

10.  Direct Oral Anticoagulants (DOAC): Are We Ready for a Pharmacogenetic Approach?

Authors:  Raffaele Palmirotta
Journal:  J Pers Med       Date:  2021-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.